In breast cancer, IL-1β is often produced by activated macrophages and dendritic cells in the tumor microenvironment, and it can also be secreted by highly aggressive breast cancer cells, particularly in triple-negative breast cancer, which exhibits aberrant inflammasome activation [14]. This evidence concerns the gene IL1B and triple-negative breast carcinoma.